Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
cache
Home
cache
Next Post
Previous Post
cache
David Dornan, PhD
January 1, 2020
/
Uncategorized
Like
this post!
Share
the Post
About
the Author
Related
Posts
Phase II Trial of
nab
-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update
ABI-009 (
nab
-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase II Registration Trial
cache
Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology
Phase 2, Multicenter Open-label Basket Trial of
nab
-Sirolimus for Malignant Solid Tumors Harboring Inactivating Alterations in
TSC1
or
TSC2
(PRECISION I)
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement
Severe Pulmonary Arterial Hypertension Treated with ABI-009,
nab
-Sirolimus, an mTOR Inhibitor
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.